NEW YORK (GenomeWeb News) – Veracyte today increased the proposed maximum aggregate offering amount for its planned initial public offering to $81.1 million.

In an amended Form S-1 filed with the US Securities and Exchange Commission today, the molecular cytology firm also announced its preliminary third quarter financial results.

Veracyte said in the SEC filing that it expects to offer 4.7 million shares at a price between $13 and $15 per share, with the intention of raising net proceeds of $58.7 million at the midpoint price of $14 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.